Cem YÜCEL, Mehmet Zeynel KESKİN, Özgür ÇAKMAK, Zafer KOZACIOĞLU

Postmenopozal kadınlarda testosteron hormonunun cinsel disfonksiyon tedavisindeki önemi: literatürün gözden geçirilmesi

Kadın cinsel disfonksiyonu, kadınların %38-63'ünü etkileyen birçok sebebe bağlı bir problemdir. Menopozla birlikte hormonal dengenin değişmesi, kadının cinsel disfonksiyonunu arttırır. Postmenopozal dönemde östrojen ile birlikte testosteron da azalır. Menopozla ortaya çıkan androjen yetersizliği, östrojen azalmasından bağımsız olarak, kronik yorgunluk, depresyon, libido azalması ve cinsel disfonksiyona yol açar. Günümüze kadar yapılmış birçok çalışma, postmenopozal kadınlarda testosteron kullanımının, östrojen terapisinden bağımsız olarak, cinsel istek, cinsel uyarılma, vajinal kan akımı, orgazm sıklığı ve cinsel tatmini olumlu yönde etkilediğini göstermiştir. Mevcut bilgiler androjenlerin kadın cinsel fonksiyonlarında önemli rol oynadığını göstermektedir. Cinsel disfonksiyonu olan postmenopozal kadınlarda transdermal testosteronun tedavide etkili olabileceği gösterilmiştir. Hâlen postmenopozal cinsel disfonksiyon semptomlarının tedavisinin testosteron veya östrojen-testosteron kombinasyonu şeklinde bir hormon preparatı kullanımı için onay alınmamıştır. Testosteron kullanımının etkinliğini ve güvenilirliğini ortaya koyacak uzun süreli çalışmalara gereksinim vardır Bu derlemede testosteron hormonunun postmenopozal kullanımının cinsel disfonksiyon tedavisindeki önemi literatür eşliğinde tartışılmıştır

The importance of testosterone in treatment of sexual dysfunction in postmenopausal women: a review of literature

Female sexual dysfunction is a problem associated with many causes affecting 38–63% of women. Alteration of hormonal balance with menopause causes female sexual dysfunction. Testosterone and estrogen levels decrease in the postmenopausal period. Menopause-induced androgen insufficiency may lead to chronic fatigue, depression, decreased libido and sexual dysfunction independent of estrogen deprivation. Many studies have reported that use of testosterone in postmenopausal women positively affects sexual desire, sexual arousal, vaginal blood flow, orgasm frequency and sexual satisfaction. The current data shows that androgens play an important role in female sexual functions. It is shown that transdermal testosterone may be effective in the treatment of postmenopausal women with sexual dysfunction. Currently, no hormone preparation such as testosterone or estrogen-testosterone has been approved in the treatment of postmenopausal sexual dysfunction. In this review, the importance of postmenopausal use of testosterone hormone in sexual dysfunction treatment has been discussed with the guide of current literature

PDF

___

KAYNAKLAR
1. Butler PA. Sexual health –a new focus for the WHO. Progress in Reproductive Health Research 2004;67:1–8.
2. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, et al. Report of the international consensus developmentconference on female sexual dysfunction: definitions and classifications. J Urol 2000;163:888–93.
3. Bayram GO, Şahin NO. Histerectomy’s psychosexual effects in turkish women. Sex Disabil 2008;26:149–58.
4. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847–53. doi: 10.1210/jc.2005-0212
5. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sufate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832–8. doi: 10.1210/jcem.85.8.6740
6. Zumof B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma estosteron concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995;80:1429– 30. doi: 10.1210/jcem.80.4.7714119
7. Haring R, Hannemann A, John U, Radke D, Nauck M, Wallaschofski H, et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatographytandem mass spectrometry. J Clin Endocrinol Metab 2012;97:408–15. doi: 10.1210/jc.2011- 2134
8. Pugeat M, Nader N, Hogeveen K, Raverot G, Déchaud H, Grenot C. Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol Cell Endocrinol 2010;316:53–9. doi: 10.1016/j.mce.2009.09.020
9. Zhuo FL, Xu W, Wang L, Wu Y, Xu ZL, Zhao JY. Androgen receptor gene polymorphisms and risk for androgenetic alopecia: a metaanalysis. Clin Exp Dermatol 2012;37:104–11. doi: 10.1111/j.1365-2230.2011.04186.x
10. Wang F, Pan J, Liu Y, Meng Q, Lv P, Qu F, et al. Alternative splicing of the androgen receptor in polycystic ovary syndrome. Proc Natl Acad Sci 2015;112:4743–8. doi: 10.1073/pnas.1418216112
11. Topic B, Tavares MC, Tomaz C, Mattern C. Prolonged effects of intra-nasally administered testosterone on proceptive behavior in female capuchin monkeys (Cebus apella). Behav Brain Res 2007;16:60–8. doi: 10.1016/j.bbr.2007.01.011
12. Tavares MC, Topic B, Abreu C, Waga I, Gomes U, Tomaz C, et al. Effects of intra-nasally administered testosterone on proceptive behavior in female capuchin monkeys (Cebus apella). Behav Brain Res 2007;16:33–42. doi: 1
13. Wahlin-Jacobsen S, Pedersen AT, Kristensen E, Læssøe NC, Lundqvist M, Cohen AS, et al. Is there a correlation between androgens and sexual desire in women? J Sex Med 2015;12:358– 73. doi: 10.1111/jsm.12774
14. Randolph JF Jr, Zheng H, Avis NE, Greendale GA, Harlow SD. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J Clin Endocrinol Metab 2015;100:258– 66. doi: 10.1210/jc.2014-1725
15. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91–6. doi: 10.1001/jama.294.1.91
16. Archer JS, Love-Geffen TE, Herbst-Damm KL, Swinney DA, Chang JR. Effect of estradiol versus estradiol and testosterone on brain-activation patterns in postmenopausal women. Menopause 2006;13:528–37. doi: 10.1097/01.gme.0000188737.46746.cd
17. Davis SR, Goldstat R, Papalia MA, Shah S, Kulkarni J, Donath S, et al. Effects of aromatase inhibition on sexual function and wellbeing in postmenopausal women treated with testosterone: a randomized placebo controlled trial. Menopause 2006;13:37–45. doi: 10.1097/01.gme.0000168061.32917.83
18. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944–52. doi: 10.1097/01.AOG.0000158103.27672.0d
19. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause 2004;11:120– 30. doi: 10.1097/01.GME.0000075502.60230.28
20. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in menopausal women not taking estrogen therapy. N Engl J Med 2008;359:2005–17. doi: 10.1056/ NEJMoa0707302
21. Snabes MC, Zborowski JD, Simes SM. Libigel (testosterone gel) does not differentiate from placebo therapy in the treatment of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2012;3:171. 22. Baldassarre M, Perrone AM, Giannone FA, Armillotta F, Battaglia C, Costantino A, et al. Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int J Impot Res 2013;25:7–11. doi: 10.1038/ijir.2012.25
23. Fernandes T, Costa-Paiva LH, Pinto-Neto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. J Sex Med 2014;11:1262–70. doi: 10.1111/jsm.12473
24. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011;16:424–31. doi: 10.1634/ theoncologist.2010-0435
25. Davis SR. Cardiovascular and cancer safety of testosterone in women. Curr Opin Endocrinol Diabetes Obes 2011;18:198–203. doi: 10.1097/MED.0b013e328344f449
26. Glaser RL, Dimitrakakis C. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole:a prospective, observational study. Maturitas 2013;76:342–9. doi: 10.1016/j.maturitas.2013.08.002